February 27, 2020
Barclays Capital has initiated coverage of the US biopharma space and will follow 16 companies in the market.
November 8, 2019
REBLOZYL is the first FDA-approved treatment of anemia in adults with beta thalassemia that require red blood cell transfusions.
April 5, 2019
Celgene (NASDAQ:CELG) and Acceleron Pharma (NASDAQ:XLRN) have announced that Celegene has submitted a biologics license application for luspatercept, which is...
June 29, 2018
Celgene (NASDAQ: CELG) and Acceleron Pharma (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study...